DU
MCRB icon

Delphia (USA)’s Seres Therapeutics MCRB Stock Holding History

Delphia (USA)’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,696
Closed -$162K – 105
2023
Q2 		$162K Buy
+1,696
New +$185K 0.26% 173
2022
Q1 		– Sell
-677
Closed -$113K – 366
2021
Q4 		$113K Buy
+677
New +$108K 0.12% 248

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Delphia (USA)'s MCRB Position: Q3 2023 in Review

Delphia (USA) sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 1,696 shares — an estimated $162K sold.

Delphia (USA) first reported a position in MCRB in Q4 2021 and held it in 2 quarters. The position peaked at $162K in Q2 2023. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

  • Delphia (USA) reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Delphia (USA) sold 1,696 Seres Therapeutics shares in Q3 2023, an estimated $162K.
  • Delphia (USA) first reported a position in Seres Therapeutics in Q4 2021 and held it in 2 quarters.
  • Delphia (USA)'s Seres Therapeutics position peaked at $162K in Q2 2023.
  • 134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Delphia (USA)'s 13F filing for Q3 2023, filed 15 Nov 2023.